BIO — Bio-Rad Laboratories, Inc. stock price, charts and financials

QT69Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. (NYSE: BIO) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
349.30
-3.18-0.90%
BIOQT69Bio-Rad Laboratories, Inc.·NYSE
349.30-0.90%
News
Down 0.9% — Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock (zacks.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index-P/E42.31EPS (ttm)8.33Insider Own8.75%Shs Outstand26.92MPerf Week8.29%
Market Cap9.49BForward P/E34.06EPS next Y10.35Insider Trans-0.02%Shs Float17.88MPerf Month18.56%
Enterprise Value10.17BPEG-EPS next Q-Inst Own-Short Float8.72%Perf Quarter36.98%
Income223.90MP/S3.66EPS this Y58.84%Inst Trans-Short Ratio4.11Perf Half Y17.67%
Sales2.59BP/B1.31EPS next Y7.32%ROA2.17%Short Interest1.56MPerf YTD16.33%
Book/sh-P/C19.14EPS next 5Y9.79%ROE3.15%52W High350.14 -0.24%Perf Year33.35%
Cash/sh-P/FCF26.87EPS past 3/5Y- -26.07%ROIC1.54%52W Low234.60 48.89%Perf 3Y-12.70%
Dividend Est.-EV/EBITDA19.03Sales past 3/5Y-2.68% 0.29%Gross Margin51.90%Volatility4.49% 3.28%Perf 5Y-52.34%
Dividend TTM-EV/Sales3.93EPS Y/Y TTM109.29%Oper. Margin9.08%ATR (14)11.73Perf 10Y143.79%
Dividend Ex-Date-Quick Ratio2.33Sales Y/Y TTM0.90%Profit Margin8.59%RSI (14)73.89Recom2.36
Dividend Gr. 3/5Y-Current Ratio3.14EPS Q/Q-25.59%SMA2010.59%Beta1.05Target Price345.00
Payout22.03%Debt/Eq0.17Sales Q/Q1.20%SMA5015.90%Rel Volume0.73Prev Close352.47
Employees7,450LT Debt/Eq0.20EarningsOct 29SMA20018.89%Avg Volume366.98KPrice349.30
IPO DateFeb 27, 1980Option/ShortYes / YesEPS/Sales Surpr.-4.21% 0.37%Net Debt/EBITDA1.28Volume266,851Change-0.90%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedRBC CapitalOutperform$370$390
Aug-05-26ReiteratedRBC CapitalOutperform$320$370
May-25-26ReiteratedWells FargoEqual Weight$290$310
May-14-26ResumedRBC CapitalOutperform$565$320
May-01-26ReiteratedWells FargoEqual Weight$320$290
Apr-07-26DowngradeCitigroupBuyNeutral
Feb-16-26ReiteratedWells FargoEqual Weight$340$320
Feb-13-26ReiteratedUBSBuy$350$335
Oct-30-25ReiteratedWells FargoEqual Weight$340
Oct-01-24UpgradeCitigroupNeutralBuy$400
Latest News
Today
Aug-07-26
Aug-06-26
Aug-05-26
Aug-04-26
Jul-28-26
Jul-27-26
Jul-23-26
Company

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,5892,5832,567
Cost of Goods Sold Incl. D&A1,2461,2401,188
Gross Profit1,3431,3441,379
Selling, General and Administrative Excl. Other848820814
Research and Development261257296
Other Operating Expense-110
Operating Income235271269
Interest Expense364949
Unusual Expense
Non-Operating Income (Expense)152774-2,563
Net Income Before Taxes350996-2,342
Income Taxes128236-498
Consolidated Net Income222760-1,844
Net Income From Continuing Operations222760-1,844
Net Income222760-1,844
EPS (Recurring)8.3327.87-65.36
EPS (Basic, Before Extraordinaries)8.3327.87-65.36
EPS (Diluted)8.2527.87-65.36
EBITDA5341,250-2,142
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio42.3410.87
Price To Sales Ratio3.643.173.58
Gross Margin51.8752.0353.72
Operating Margin9.0810.4910.48
Net Margin8.5729.42-71.83
Shares Outstanding272728
Market Capitalization9,4318,1819,198
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$372.86$328.69$284.51$240.34$196.17 Close Price0.00K53.57K107.14K160.72K214.29KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
ENGELHARDT EVA ANETTEEVP, President, CDGJul 25 '26Option Exercise0.002460592Jul 28
ENGELHARDT EVA ANETTEEVP, President, CDGMay 11 '26Sale246.54550135,597346May 13
ENLOE COURTNEY CEVP, General Counsel & SecApr 24 '26Option Exercise0.001860827Apr 28
Lakkaraju Roop KalyanEVP, Chief Financial OfficerApr 24 '26Option Exercise0.001,07802,984Apr 28
EDWARDS JEFFREY LDirectorApr 21 '26Option Exercise0.004070715Apr 23
Hinckley Greg KDirectorApr 21 '26Option Exercise0.0040701,215Apr 23
PEI MELINDA LITHERLANDDirectorApr 21 '26Option Exercise0.004070715Apr 23
PINKSTON ARNOLD ADirectorApr 21 '26Option Exercise0.004070715Apr 23
BARRY JAMESEVP, President, LSGNov 06 '25Sale306.18700214,289510Nov 10
DiVincenzo Jonathan P.President & COOOct 24 '25Option Exercise0.001,86901,869Oct 28
EVRAN SEDATEVP, Global Supply ChainOct 20 '25Option Exercise0.001,04402,568Oct 21
Allison SchwartzDirectorSep 01 '25Option Exercise0.0029401,452Sep 03
BARRY JAMESEVP, President, LSGSep 01 '25Option Exercise0.001,2040749Sep 03
COREY COLLEENEVP, Global Human ResourcesSep 01 '25Option Exercise0.002,204019,581Sep 03
SCHWARTZ NORMAN DChairman & CEOSep 01 '25Option Exercise0.0012,7060444,591Sep 03
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.